insights_auto
Why is REGN up 2.18%?
Dive Deeperchevron_right
REGN:NASDAQ
Regeneron Pharmaceuticals Inc
$762.81
arrow_upward
+2.18%(+16.27) 1D
$762.81
0.00% (0.00)
bedtimeAfter hours
Closed: Oct 12, 4:00:00 PM GMT-4 · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for REGN...
Open
$748.67
High
$768.66
Low
$744.96
Mkt. cap
78.54B
Avg. vol.
710.65K
Volume
129.00
Dividend
0.49%
Quarterly dividend
$0.94
Ex-dividend date
Aug 18, 2026
P/E ratio
18.86
52-wk high
$859.34
52-wk low
$541.00
EPS
$40.45
Beta
0.16
Shares outstanding
101.14M
No. of employees
15K
Open
$748.67
High
$768.66
Low
$744.96
Mkt. cap
78.54B
Avg. vol.
710.65K
Volume
129.00
Dividend
0.49%
Quarterly dividend
$0.94
Ex-dividend date
Aug 18, 2026
P/E ratio
18.86
52-wk high
$859.34
52-wk low
$541.00
EPS
$40.45
Beta
0.16
Shares outstanding
101.14M
No. of employees
15K
News stories
From web sources and news partners
The Globe and Mail
·
1 hour ago
Citi Keeps Their Hold Rating on Regeneron (REGN)
ad-hoc-news.de
·
2 hours ago
Regeneron reports Pasatru data and Citi holds Regeneron stock
ad-hoc-news.de
·
3 hours ago
Sanofi expanded Regeneron alliance: Sanofi stock gains 1.34 percent
ad-hoc-news.de
·
5 hours ago
Regeneron reports 84-week Pasatru results: stock pre-market at EUR 684.95
Profile
Regeneron Pharmaceuticals, Inc. is an American biotechnology company headquartered in Westchester County, New York. The company was founded in 1988. Originally focused on neurotrophic factors and their regenerative capabilities, giving rise to its present name; the company has since expanded operations into the study of both cytokine and tyrosine kinase receptors, which gave rise to their first product, which is a VEGF-trap. Wikipedia
About Regeneron Pharmaceuticals Inc
CEOLeonard Schleifer
Employees15.3K
Founded1988
HeadquartersTarrytown, New York, United States
SectorBiotechnology
Websiteregeneron.com